ALK and anaplastic large cell lymphoma: NVP-BGT226 has also been shown to exert cytotoxic effects against other cancer cell types such as ALK-positive anaplastic large cell lymphoma [615] and hepatocellular carcinoma [616] and has entered Phase I/II clinical trials for breast cancer [617].